Radius Health Stock News

Shares of Radius Health, Inc. (NASDAQ:RDUS) have been assigned an average recommendation of Hold from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average []

Radius Health, Inc. (NASDAQ:RDUS) Equities research analysts at SVB Leerink dropped their FY2022 earnings per share estimates for Radius Health in a research note issued on Thursday, December 9th. SVB Leerink analyst G. Porges now forecasts that the biopharmaceutical company will post earnings per share of $0.31 for the year, down from their previous []

Radius Health, Inc. (NASDAQ:RDUS) major shareholder Rubric Capital Management Lp acquired 768,171 shares of the stock in a transaction dated Friday, December 10th. The shares were bought at an average cost of $7.17 per share, with a total value of $5,507,786.07. The purchase was disclosed in a filing with the Securities & Exchange Commission, which []

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. U.S.

Radius Health, Inc. (NASDAQ:RDUS) major shareholder Rubric Capital Management Lp acquired 560,691 shares of the stock in a transaction that occurred on Wednesday, December 8th. The stock was purchased at an average price of $8.02 per share, for a total transaction of $4,496,741.82. The transaction was disclosed in a legal filing with the Securities & []

Radius Health (NASDAQ:RDUS) had its price target trimmed by HC Wainwright from $23.00 to $10.00 in a research note issued to investors on Thursday, The Fly reports. The firm currently has a neutral rating on the biopharmaceutical companys stock. RDUS has been the topic of several other research reports. The Goldman Sachs Group upped their []

SVB Leerink restated their hold rating on shares of Radius Health (NASDAQ:RDUS) in a research report sent to investors on Thursday, Analyst Ratings Network reports. They currently have a $20.00 price target on the biopharmaceutical companys stock, down from their previous price target of $30.00. A number of other equities analysts have also recently issued []

Radius Health, Inc. (NASDAQ:RDUS) was the recipient of some unusual options trading on Wednesday. Stock investors acquired 6,812 call options on the stock. This represents an increase of 715% compared to the average daily volume of 836 call options. RDUS stock opened at $7.60 on Friday. Radius Health has a twelve month low of $7.39 []

Radius Health (NASDAQ:RDUS) was downgraded by stock analysts at The Goldman Sachs Group from a buy rating to a neutral rating in a research note issued on Thursday, The Fly reports. Several other research analysts have also recently issued reports on RDUS. SVB Leerink reaffirmed a hold rating and set a $20.00 target price (down []

Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.

After posting three straight days of gains, U.S. market indexes were down on Thursday morning in anticipation of the consumer price index for November being released by the Labor Department on Friday.

Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.

Radius Health (NASDAQ:RDUS)s stock had its hold rating reissued by equities research analysts at SVB Leerink in a research note issued to investors on Thursday, AnalystRatings.com reports. Several other brokerages also recently issued reports on RDUS. Bank of America began coverage on shares of Radius Health in a research note on Friday, December 3rd. They [] The post Radius Healths (RDUS) Hold Rating Reaffirmed at SVB Leerink appeared first on ETF Daily News .

Today''s Daily Dose brings you news about the first antibody therapy for the prevention of COVID-19, the FDA panel review of Reata Pharma''s Alport syndrome drug; disappointing data from Radius Health''s wearABLe study; and encouraging new data of Zymeworks'' Zanidatamab in breast cancer.

A closer look at the clinical trial results that drove the stock up in October was a little disappointing.